Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults

Phase 3

Terminated

Conditions: Tonsillitis
Pharyngitis

First Posted Date: 2006-04-18

Last Posted Date: 2009-04-03

Lead Sponsor: Sanofi

Target Recruit Count: 233

Registration Number: NCT00315549

Locations: 🇨🇷
Sanofi-Aventis, San Jose, Costa Rica

TELI TON - Telithromycin in Tonsillitis

Phase 3

Terminated

Conditions: Tonsillitis
Pharyngitis

First Posted Date: 2006-04-17

Last Posted Date: 2009-04-03

Lead Sponsor: Sanofi

Target Recruit Count: 314

Registration Number: NCT00315042

Locations: 🇵🇦
Sanofi-Aventis, Panama, Panama

TELI COM - Telithromycin in Children With Otitis Media

Phase 3

Terminated

Conditions: Otitis Media, Suppurative
Otitis Media, Purulent

First Posted Date: 2006-04-17

Last Posted Date: 2009-04-03

Lead Sponsor: Sanofi

Target Recruit Count: 1500

Registration Number: NCT00315003

Locations: 🇵🇪
Sanofi-Aventis, Lima, Peru

Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

Phase 3

Completed

Conditions: Encephalitis
Japanese Encephalitis

Interventions: Biological: 0.9% Saline
Biological: ChimeriVax-JE, Japanese Encephalitis vaccine

First Posted Date: 2006-04-13

Last Posted Date: 2012-12-06

Lead Sponsor: Sanofi

Target Recruit Count: 2004

Registration Number: NCT00314132

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

Phase 3

Completed

Conditions: Japanese Encephalitis

Interventions: Biological: ChimeriVax™-JE
Biological: JE-VAX®

First Posted Date: 2006-04-13

Last Posted Date: 2012-12-06

Lead Sponsor: Sanofi

Target Recruit Count: 820

Registration Number: NCT00314145

Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia

Phase 2

Completed

Conditions: Fibromyalgia
Sleep
Chronic Pain

Interventions: Drug: eplivanserin (SR46349)
Drug: placebo

First Posted Date: 2006-04-12

Last Posted Date: 2010-11-30

Lead Sponsor: Sanofi

Target Recruit Count: 205

Registration Number: NCT00313885

Locations: 🇺🇸
Wichita Clinic PA, Wichita, Kansas, United States
🇺🇸
Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
🇺🇸
Renstar Medical Research, Ocala, Florida, United States

and more 9 locations